Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDX-1197 in Combination With XELOX or Irinotecan in Advanced Gastric Cancer
NCT04725994Phase 2Active, not recruiting
- Sponsor
- Idience
- Start
- Jun 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of venadaparib in gastric cancer (GC), sponsored by Idience. Started Jun 2021; status: active, not recruiting.
02
Drugs
venadaparib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04725994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725994.